(RS)-<1-(benzyloxycarbonyl)amino>-butan-2,4-diol | 157542-04-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (RS)-<1-(benzyloxycarbonyl)amino>-butan-2,4-diol
• 英文别名: Benzyl (2,4-dihydroxybutyl)carbamate；benzyl N-(2,4-dihydroxybutyl)carbamate
• CAS: 157542-04-6
• 化学式: C₁₂H₁₇NO₄
• 分子量: 239.271
• InChiKey: RKCMHVFAZKDZGA-UHFFFAOYSA-N

物化性质

• 沸点：
  463.8±45.0 °C(Predicted)
• 密度：
  1.220±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  78.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (RS)-<1-(benzyloxycarbonyl)amino>-butan-2,4-diol 在 咪唑 、 二乙胺基三氟化硫 、 碘 、 sodium hydride 、 三苯基膦 、 cesium fluoride 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 28.0h， 生成 [(2-fluoro-4-iodobutyl)(methyl)amino]methanoic acid benzyl ester
  参考文献：
  名称：

  [EN] PYRIMIDINE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE
  [FR] COMPOSÉ HÉTÉROCYCLIQUE DE PYRIMIDINE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION EN MÉDECINE
  [ZH] 嘧啶杂环化合物，其制法与医药上的用途

  摘要：

  一种嘧啶杂环化合物，其制法与医药上的用途。具体地，结构如式（A）所示的嘧啶杂环化合物或其药学上可接受的盐，各基团定义如说明书中所定义；包含所述化合物的药物组合物以及所述化合物在治疗细胞增殖性疾病（例如癌症）等中的用途。

  公开号：

  WO2023116761A1
• 作为产物：
  描述：

  methyl (RS)-<4-(benzyloxycarbonyl)amino>-3-hydroxybutyrate 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 4.5h， 以40%的产率得到(RS)-<1-(benzyloxycarbonyl)amino>-butan-2,4-diol
  参考文献：
  名称：

  Absolute configuration of main chain of AAL-toxins.

  摘要：

  AAL-toxins TA(1) 1 and TA(2) 2, host-specific toxins produced by Alternaria alternata, were degraded to 2-methylbutanol, 3-methylnonan-1,9-diol and N-protected 4-aminobutan-1-3-diol, which were further converted to (R)-MTPA esters. These esters were correlated with synthesis samples by comparison of their 500 MHz H-1-NMR spectra. The remaining stereocenters were determined by the comparison of H-1-NMR spectra of 6a and 7 derived from 1 and 2 with those of synthetic model compounds. These data conclude that AAL-toxins possess 2S, 4S, 5R, 11S, 13S, 14R and 15R configurations.

  DOI：

  10.1016/s0040-4020(01)89343-1

文献信息

• Absolute configuration of C(1)C(5) fragment of AAL-toxin: Conformationally rigid acyclic aminotriol moiety
  作者：Hideaki Oikawa、Isamu Matsuda、Akitami Ichihara、Keisuke Kohmoto

  DOI：10.1016/0040-4039(94)88029-8

  日期：1994.2

  Degradation of AAL-toxin 1 a host-specific phytotoxin and synthesis of model aminotriol 7a - 7d allowed us to determine the absolute configuration of C(1)C(5) fragment as 2S, 4S and 5R. Unusually rigid conformation of this acyclic fragment was also discussed.

  AAL-毒素降解1宿主特异性植物毒素和模型aminotriol的合成图7a - 7D使我们能够确定C的绝对构型（1）C（5）片段作为2小号，4小号和5 - [R 。还讨论了该无环片段的异常刚性构象。
• BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1
  申请人：Furet Pascal

  公开号：US20150126485A1

  公开（公告）日：2015-05-07

  The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the tyrosine kinase enzymatic activity of the Abelson protein (ABL1), the Abelson-related protein (ABL2) and related chimeric proteins, in particular BCR-ABL1. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

  本发明涉及式（I）的化合物：其中Y，Y，R，R2，R3和R4在本发明的摘要中定义；能够抑制Abelson蛋白（ABL1），Abelson相关蛋白（ABL2）和相关嵌合蛋白的酪氨酸激酶酶活性，特别是BCR-ABL1。本发明还提供了制备本发明化合物的方法，包括这种化合物的制药制剂以及使用这种化合物治疗癌症的方法。
• Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
  申请人：Furet Pascal

  公开号：US09340537B2

  公开（公告）日：2016-05-17

  The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the tyrosine kinase enzymatic activity of the Abelson protein (ABL1), the Abelson-related protein (ABL2) and related chimeric proteins, in particular BCR-ABL1. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

  本发明涉及式（I）的化合物：其中Y，Y，R，R2，R3和R4在本发明摘要中定义；能够抑制Abelson蛋白（ABL1），Abelson相关蛋白（ABL2）和相关嵌合蛋白的酪氨酸激酶酶活性，特别是BCR-ABL1。本发明还提供了制备本发明化合物的方法，包括这种化合物的制药配制物以及使用这种化合物治疗癌症的方法。
• COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1
  申请人：FURET Pascal

  公开号：US20180134695A1

  公开（公告）日：2018-05-17

  The present invention relates to compounds of formula (I): in which Y, Y 1 , R 1 , R 2 , R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the tyrosine kinase enzymatic activity of the Abelson protein (ABL1), the Abelson-related protein (ABL2) and related chimeric proteins, in particular BCR-ABL1. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.
• US9340537B2
  申请人：——

  公开号：US9340537B2

  公开（公告）日：2016-05-17